INO - Inovio Pharmaceuticals, Inc.
| Previous Close | 4.29 |
| Open | 4.26 |
| Bid | 3.90 x 4000 |
| Ask | 5.63 x 2900 |
| Day's Range | 4.17 - 4.34 |
| 52 Week Range | 3.64 - 7.00 |
| Volume | 434,505 |
| Avg. Volume | 882,687 |
| Market Cap | 392.956M |
| Beta | 1.68 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.15 |
| Earnings Date | May 8, 2018 - May 14, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.20 |
- ACCESSWIRE•7 days ago
Free Technical Research on Insmed and Three More Biotech Equities
On Thursday, July 12, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Wednesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Innoviva Inc. (NASDAQ: INVA), Inovio Pharmaceuticals Inc. (NASDAQ: INO), and Insmed Inc. (NASDAQ: INSM).
- Motley Fool•12 days ago
Is Inovio Pharmaceuticals, Inc. a Buy?
This clinical-stage biotech has a promising pipeline. But it faces significant risks, too.
- GlobeNewswire•23 days ago
Inovio’s MERS Vaccine Generates High Levels of Antibodies and Induces Broad-based T Cell Responses in Phase 1 Study
Inovio Pharmaceuticals, Inc. (INO) today announced positive Phase 1 results of its collaborative vaccine study with INO-4700 (GLS-5300) against MERS (Middle East Respiratory Syndrome). Results for INO-4700, which is being co-developed by Inovio and GeneOne Life Science Inc. (KSE:011000), showed that the drug was well-tolerated and demonstrated overall high levels of antibody responses in roughly 95% of subjects, while also generating broad-based T cell responses in nearly 90% of study participants. The Phase 1, open-label, dose-escalation MERS vaccine trial, in partnership with the Walter Reed Army Institute of Research in Maryland, displayed antibody responses by ELISA in 94% of subjects at week 14 (two weeks post-third dose).
- Motley Fool•28 days ago
Better Buy: Inovio Pharmaceuticals, Inc. vs. Achillion Pharmaceuticals, Inc.
Which stock wins in a battle between these two clinical-stage biotechs?
- GlobeNewswire•29 days ago
Inovio Announces Treatment of First Patient in Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron’s PD-1 Inhibitor
Inovio Pharmaceuticals, Inc. (INO) today announced that it has dosed its first patient as part of its Phase 1/2 immuno-oncology trial in patients with newly diagnosed glioblastoma (GBM). The efficacy trial is designed to evaluate Inovio’s INO-5401 T cell activating immunotherapy encoding multiple antigens expressed by GBM and INO-9012, an immune activator encoding IL-12, in combination with cemiplimab (REGN2810), a PD-1 inhibitor developed by Regeneron Pharmaceuticals. Dr. J. Joseph Kim, Inovio's President and Chief Executive Officer, said, “GBM is a devastating cancer, and malignant glioma has already claimed the lives of Senator Ted Kennedy and Beau Biden, the son of the former Vice President Joe Biden.
- Motley Fool•last month
Are These 2 Dark Horse Vaccine Makers Worth the Risk?
A new industry report suggests that Novavax and Inovio Pharmaceuticals might be grossly undervalued right now.
- Zacks•last month
Inovio (INO) Down 5.8% Since Earnings Report: Can It Rebound?
Inovio (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire•2 months ago
Inovio CEO to Speak on Viral Epidemic Preparedness Panel at BIO International Convention
PLYMOUTH MEETING, Pa., May 31, 2018-- Inovio Pharmaceuticals, Inc. today announced that Dr. J. Joseph Kim, President and CEO, will address Inovio’ s ability to respond to emerging viral threats at the ...
- GlobeNewswire•2 months ago
Inovio Boosts Leadership Focused on Partnership and Grant Funding By Appointing Two New VPs for Business Development and R&D
Inovio Pharmaceuticals, Inc. (INO) today announced that it has bolstered its efforts to attract partnerships and collaborations and increase non-dilutive funding with the hiring of an accomplished business development leader and the promotion of a key R&D leader. Mr. Shawn D. Bridy joins Inovio as Vice President of Business Development reporting to Dr. J. Joseph Kim, President & CEO. Mr. Bridy has more than 20 years of business development & licensing, commercial strategy, and transaction experience in the life sciences industry.
- Zacks•2 months ago
Inovio Initiates Phase II Study on Pipeline Drug VGX-3100
Inovio (INO) begins a phase II study to evaluate the efficacy of its pipeline candidate VGX-3100 on adult men and women with human papilloma virus (HPV)-related anal dysplasia.
- GlobeNewswire•2 months ago
Inovio Opens Phase 2 Trial for VGX-3100 in Third Indication To Treat HPV – The No. 1 Sexually Transmitted Disease
Inovio Pharmaceuticals, Inc. (INO) today announced that it has commenced a Phase 2 clinical trial to evaluate the efficacy of VGX-3100 in adult men and women with human papilloma virus (HPV)-related anal dysplasia. Recruitment is ongoing for patients who are HIV-negative with histologically confirmed anal or perianal high-grade squamous intraepithelial lesions (HSIL) associated with HPV-16 and/or HPV-18. Anal HSIL or dysplasia is the precursor to anal cancer, which is estimated to cause more than 1,100 deaths in the United States in 2018.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of INO earnings conference call or presentation 9-May-18 8:30pm GMT
Q1 2018 Inovio Pharmaceuticals Inc Earnings Call
- GlobeNewswire•2 months ago
Inovio Pharmaceuticals Demonstrates PSA Stabilizing Effect of INO-5150 Immunotherapy in Phase 1b Study for Prostate Cancer
PLYMOUTH MEETING, Pa., May 17, 2018-- Inovio Pharmaceuticals, Inc. today announced a poster presentation of additional prostate cancer data at the American Society of Clinical Oncology annual meeting to ...
- Zacks•2 months ago
Inovio Pharmaceuticals (INO) in Focus: Stock Moves 5.7% Higher
Inovio Pharmaceuticals (INO) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
- ACCESSWIRE•2 months ago
Today’s Research Reports on Stocks to Watch: Heat Biologics, Inc. and Inovio Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / May 16, 2018 / Shares of biotech stocks Heat Biologics and Inovio Pharmaceuticals both saw gains in Tuesday's trading session. It was a positive data update on Inovio's HIV ...
- GlobeNewswire•2 months ago
Inovio HIV Vaccine, Which Generated Near 100% Immune Responses, Sustained Durable Memory Responses Measured One Year After The Start of Clinical Trial
Inovio Pharmaceuticals, Inc. (INO) today announced that its HIV vaccine, PENNVAX®-GP, maintained durable and robust immune responses at month 12, a full six months after the last dose in a Phase 1 clinical study. Inovio previously reported that PENNVAX-GP elicited the highest overall levels of immune response rates (cellular and humoral) ever demonstrated in a human study by an HIV vaccine. To potentially prevent and treat HIV, PENNVAX-GP consists of a combination of four HIV antigens designed to generate both antibody and T-cell responses and cover multiple global HIV strains.
- Zacks•2 months ago
Inovio's (INO) Q1 Loss Wider than Expected, Shares Down
Inovio (INO) reports wider-than-expected loss and revenues miss estimates in the first quarter of 2018.
- Benzinga•2 months ago
Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 9) ABIOMED, Inc. (NASDAQ: ABMD ) Adaptimmune Therapeutics PLC – ...
- Associated Press•2 months ago
Inovio: 1Q Earnings Snapshot
The Plymouth Meeting, Pennsylvania-based company said it had a loss of 36 cents per share. The drugmaker posted revenue of $1.5 million in the period. In the final minutes of trading on Wednesday, the ...
- GlobeNewswire•2 months ago
Inovio Pharmaceuticals Reports 2018 First Quarter Financial Results
PLYMOUTH MEETING, Pa., May 09, 2018-- Inovio Pharmaceuticals, Inc., a late-stage biotechnology company focused on the discovery, development, and commercialization of DNA immunotherapies targeted against ...
- Benzinga•2 months ago
The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More
After eking out a modest gain in the week ended April 27, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) pulled back this week amid some not-so-encouraging earnings reports and negative regulatory ...
- Zacks•3 months ago
What's in the Cards for Inovio (INO) This Earnings Season?
Inovio's (INO) most advanced pipeline candidate, VGX-3100's progress remains in focus. However, lack of an approved product in the company's portfolio is a dampener.
- Motley Fool•3 months ago
Is Inovio Pharmaceuticals, Inc. (INO) a Buy?
Weighing the arguments for and against the clinical-stage biotech.
- GlobeNewswire•3 months ago
Inovio Pharmaceuticals to Report First Quarter 2018 Financial Results on May 9, 2018
PLYMOUTH MEETING, Pa., April 30, 2018-- Inovio Pharmaceuticals, Inc. announced today that it will host a conference call and live webcast to report its 2018 first quarter financial results on Wednesday, ...
